Related Experiment Video

Updated: Feb 7, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue

Yi Que1, Yao Liang2, Jingjing Zhao1

  • 1Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China, zhangxing@sysucc.org.cn.

Cancer Management and Research
|July 28, 2018
PubMed
Abstract

Insights

This study compared adverse effects of pazopanib, sorafenib, and sunitinib in soft tissue sarcoma patients. Sorafenib and sunitinib showed higher rates of severe mucositis, while pazopanib had more nausea and diarrhea.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Tyrosine kinase inhibitors (TKIs) are investigated for soft tissue sarcoma.
  • Pazopanib, sorafenib, and sunitinib target tyrosine kinase signaling pathways.
  • Understanding adverse effect profiles is crucial for treatment selection.

Purpose of the Study:

  • To determine the frequency of severe adverse effects in soft tissue sarcoma patients treated with pazopanib, sorafenib, and sunitinib.
  • To compare the incidence of all-grade and severe adverse events (AEs) among these three TKIs.

Main Methods:

  • A pooled analysis of 10 clinical trials (2009-2016) involving 843 patients.
  • Comprehensive literature search across major databases (PubMed, Web of Science, Embase, etc.) up to May 2017.
  • Analysis of all-grade and severe (grade ≥3) adverse events.

Main Results:

  • Pazopanib showed higher incidence of nausea, diarrhea, and hypertension compared to sorafenib and sunitinib.
  • Sorafenib group had significantly higher rates of all-grade rash, hand-foot syndrome, and mucositis.
  • Sunitinib group exhibited a significantly higher frequency of severe mucositis compared to pazopanib and sorafenib.

Conclusions:

  • Statistically significant differences in common adverse effects exist among pazopanib, sorafenib, and sunitinib.
  • Prompt management of AEs is essential to prevent dose reductions and treatment discontinuations.
  • This comparative analysis aids in optimizing TKI selection for soft tissue sarcoma.
Keywords:
pazopanibsoft tissue sarcomasorafenibsunitinib

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

979

Related Concept Videos

Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
815
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
845
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
806
Sample Preparation for Analysis: Advanced Techniques01:08

Sample Preparation for Analysis: Advanced Techniques

Accurate analysis of complex samples often requires advanced preparation techniques to achieve reliable and reproducible results. Samples containing inorganic or organic materials can be challenging to dissolve or decompose effectively. Standard sample preparation methods include acid digestion, fusion, dry ashing, and wet digestion.
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
1.5K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
239
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K